Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study

[1]  G. Mufti,et al.  Apoptosis and its significance in MDS: controversies revisited. , 1999, Leukemia research.

[2]  H P Koeffler,et al.  Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. , 1999, Blood.

[3]  W. Hofmann,et al.  Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. , 1999, Experimental hematology.

[4]  A. Ganser,et al.  Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor , 1999, Annals of Hematology.

[5]  N. Komatsu,et al.  Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myelodysplastic syndrome. , 1999, Experimental hematology.

[6]  S. Soignet,et al.  Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia , 1998, Leukemia.

[7]  V. Santini,et al.  DIFFERENTIATION THERAPY OF MYELODYSPLASTIC SYNDROMES: FACT OR FICTION? , 1998, British journal of haematology.

[8]  J. Marshall,et al.  Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Parker,et al.  Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes , 1998, British journal of haematology.

[10]  Y Yoshida,et al.  Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. , 1998, Haematologica.

[11]  T Hamblin,et al.  International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.

[12]  L. Hoefsloot,et al.  Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. , 1997, Blood.

[13]  A. Ganser,et al.  Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. , 1997, Leukemia & lymphoma.

[14]  A. Pileri,et al.  Combined differentiating therapy for myelodysplastic syndromes: a phase II study. , 1996, Leukemia research.

[15]  A. Ganser,et al.  Myelodysplastic syndromes: clinical features. , 1996, Seminars in hematology.

[16]  H. Koeffler,et al.  Differentiation therapy in myelodysplastic syndromes. , 1996, Seminars in hematology.

[17]  A. Ganser,et al.  Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and α-tocopherol , 1996, Annals of Hematology.

[18]  M. Kris,et al.  Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  M. Asaka,et al.  All-Trans Retionic ACid in the Treatment of Myelodysplastic Syndromes , 1995 .

[20]  D. Bowen.  What is ineffective erythropoiesis in myelodysplastic syndromes? , 1995, Leukemia & lymphoma.

[21]  P. Chambon,et al.  Developmental roles of the retinoic acid receptors , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  T. Martin,et al.  Regulation and regulatory role of the retinoids. , 1995, Critical reviews in eukaryotic gene expression.

[23]  C. Finelli,et al.  All-trans retinoic acid in the treatment of myelodysplastic syndromes. , 1995, Leukemia & lymphoma.

[24]  D. Mangelsdorf,et al.  Vitamin A receptors. , 2009, Nutrition reviews.

[25]  W. Bollag.  Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25‐dihydroxyvitamin D3, and analogs , 1994, Journal of cellular biochemistry.

[26]  K. Sawada,et al.  Impaired proliferation and differentiation of myelodysplastic CD34+ cells. , 1994, Leukemia & lymphoma.

[27]  A. Ganser,et al.  Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. , 1994, Leukemia.

[28]  Pemrick Sm,et al.  The retinoid receptors. , 1994 .

[29]  H. Koeffler,et al.  Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-alpha and retinoid X receptor-alpha RNA by HL-60 cells. , 1993, Blood.

[30]  N. Gattermann,et al.  All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. , 1993, Blood.

[31]  A. Ganser,et al.  Induction of TNF‐α in patients with myelodysplastic syndromes undergoing treatment with interleukin‐3 , 1993, British journal of haematology.

[32]  H. Stunnenberg.  Mechanisms of transactivation by retinoic acid receptors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[33]  H. Koeffler,et al.  9-cis-retinoic acid : effects on normal and leukemic hematopoiesis in vitro , 1993 .

[34]  R. Warrell,et al.  Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1992, Cancer research.

[35]  H. Koeffler,et al.  Differentiation-inducing agents in the treatment of myelodysplastic syndromes. , 1992, Seminars in oncology.

[36]  K. Umesono,et al.  Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling , 1992, Nature.

[37]  Gregor Eichele,et al.  9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.

[38]  J. Grippo,et al.  9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα , 1992, Nature.

[39]  G. Morriss-Kay.  Retinoic acid receptors in normal growth and development. , 1992, Cancer surveys.

[40]  Christine Chomienne,et al.  The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.

[41]  P. Nowell,et al.  Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. , 1990, The American journal of medicine.

[42]  E. Kimby,et al.  Treatment of myelodysplastic syndromes with retinoic acid and 1α‐hydroxy‐vitamin D3 in combination with low‐dose ara‐C is not superior to ara‐C alone. Results from a randomized study , 1990 .

[43]  Christine Chomienne,et al.  The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.

[44]  R. Evans,et al.  Nuclear receptor that identifies a novel retinoic acid response pathway , 1990, Nature.

[45]  E. Kimby,et al.  Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). , 1990, European journal of haematology.

[46]  G. Gahrton,et al.  Therapeutic effects of low‐dose cytosine arabinoside, alpha‐interferon, 1α‐hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes , 1988, European journal of haematology.

[47]  D. Heitjan,et al.  Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. , 1988, Blood.

[48]  Pierre Chambon,et al.  A human retinoic acid receptor which belongs to the family of nuclear receptors , 1987, Nature.

[49]  H. Gralnick,et al.  Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.